S&P Global Market Intelligence presents a weekly rundown of recent executive changes at pharmaceutical, biotech, and life sciences companies.
* Innoviva Inc. appointed Eric d'Esparbes as its interim principal executive officer. Eric d'Esparbes will succeed Michael Aguiar, who resigned as the president, CEO and a director of the company. D'Esparbes will also continue to serve as the company's CFO and senior vice president.
* Matthew Walsh is leaving Catalent Inc. to join Allergan plc as executive vice president and CFO.
* Gerresheimer AG said Christian Fischer will resign as board chairman and CEO due to personal reasons. Gerresheimer will be managed by three board members until a new CEO has been appointed.
* Sarah Noonberg resigned as Prothena Corp. plc's chief medical officer, effective March 15. Martin Koller, the company's former chief medical officer, will provide leadership for Prothena's clinical and medical organizations on a consulting basis while the company searches for a replacement.
* The Proteostasis Therapeutics Inc. board elected Marija Zecevic COO. Zecevic had been serving as the company's chief business officer since March 2017.
* Pernix Therapeutics Holdings Inc. promoted Angus Smith to the position of senior vice president, chief business officer, and principal financial officer. Smith joined Pernix in September 2014 as vice president of M&A and corporate finance and was appointed vice president of business development and strategic planning in July 2016.
* David Kendall will become MannKind Corp.'s chief medical officer Feb. 12. Kendall, who has over three decades of experience, will replace Raymond Urbanski, who stepped down to pursue an opportunity elsewhere.
* T2 Biosystems Inc. appointed John Sprague CFO after the resignation of Darlene Deptula-Hicks.
* Bellicum Pharmaceuticals Inc. appointed William Grossman its chief medical officer. Most recently, Grossman served as the group medical director of cancer immunotherapy at Genentech Inc., a unit of Roche Holding AG.
* Panna Sharma is stepping down as the president, CEO and a director of Cancer Genetics Inc. John Roberts, Cancer Genetics' COO, will serve as interim CEO.
* Trevena Inc. appointed Carrie Bourdow its COO. Bourdow, who will also serve as an executive vice president, was promoted from senior vice president and chief commercial officer.
* Motif Bio plc said Robert Dickey IV resigned as CFO of the company. Dickey, who assumed CFO duties January 2017, will continue to serve in an advisory capacity to ensure a smooth transition. The biopharmaceutical company said it has started the search process for a new CFO, while its nonexecutive director Jonathan Gold has agreed to serve as interim CFO.
* Arcturus Therapeutics Ltd. said its board decided to terminate the employment of President and CEO Joseph Payne. The company said the decision is not related to the biotechnology company's operational performance, ongoing programs, financial condition or financial reporting.